Reich, Kristian, Eric Simpson, Richard Langley, Richard Warren, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Le Gjerum, Anna Carlsson, Melinda Gooderham, Andreas Pinter, Marjolein De Bruin Weller, and Andrew Blauvelt. “Tralokinumab Demonstrated a Consistent Safety Profile With up to 42 Months of Treatment in Moderate to Severe Atopic Dermatitis: Including Adverse Events of Special Interest”. SKIN The Journal of Cutaneous Medicine 7, no. 2 (March 13, 2023): s143. Accessed July 3, 2024. https://jofskin.org/33014/index.php/skin/article/view/2027.